Use of human IGF-1 to treat cardiac disorders
US5434134A · kind A · utility
18Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 7, 1993 |
| Grant date | Jul 18, 1995 |
| Priority date | — |
| Expiry date | Oct 7, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human IGF-I or effective analogues thereof are used for preventing or treating cardiac disorders. Compositions are also provided that comprise human IGF-I or effective analogues thereof together with additional proteins or peptides such as other growth factors, hormones, binding proteins or receptors for enhancing or improving the desired effects of IGF-I or its effective analogues and possibly pharmaceutically acceptable carrier or diluent for the prevention or treatment of cardiac disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.